omniture

LKK Health Products Group Promotes International Communication around Chinese Medicine

HONG KONG, Sept. 2, 2016 /PRNewswire/ -- Mr. Harry Yeung, Founding Director of the Modernized Chinese Medicine International Association (MCMIA) and Senior Vice President of LKK Health Products Group, attended the 12th International Conference of the Modernization of Chinese Medicine & Health Products (ICMCM) and International Postgraduate Symposium on Chinese Medicine in Hong Kong on August 11th and 12th. ICMCM is jointly initiated and hosted by the Hong Kong Trade Development Council and MCMIA.

Mr. Harry Yeung, Founding Director of the Modernized Chinese Medicine International Association (MCMIA) and Senior Vice President of LKK Health Products Group, attended the 12th International Conference of the Modernization of Chinese Medicine & Health Products (ICMCM) and International Postgraduate Symposium on Chinese Medicine in Hong Kong on August 11th and 12th.
Mr. Harry Yeung, Founding Director of the Modernized Chinese Medicine International Association (MCMIA) and Senior Vice President of LKK Health Products Group, attended the 12th International Conference of the Modernization of Chinese Medicine & Health Products (ICMCM) and International Postgraduate Symposium on Chinese Medicine in Hong Kong on August 11th and 12th.

Infinitus, a member of LKK Health Products Group, has participated in this conference since 2009 and has hosted several themed forums with the aim of conveying to the general public how Chinese medicine can serve in the prevention of disease. Infinitus also provides impetus to the modernization and globalization of Chinese medicine.

As the guest host of the CEO Forum and the International Postgraduate Symposium on Chinese Medicine, Mr. Yang said: "During this year's Summer Games, cupping glass, a form of traditional Chinese medicine treatment, became a popular catchword. American gold medal winner and swimming athlete Michael Phelps is, himself, a big fan of the cupping glass treatment. In addition to this, Chinese medical therapies such as massage and acupuncture are also very popular among international athletes. We can now say with confidence that Chinese medicine has moved beyond the borders of its home market and is being widely applied and accepted by the world at large."

As a form of treatment which has been around for well more than a thousand years, and perfected through multiple generations of experience, Chinese medicine is becoming ever more popular across the global market. At this year's ICMCM, Wang Xiaopin, the general director of State Administration of Traditional Chinese Medicine, indicated in her speech entitled Opportunities under the Belt and Road Initiative: "In most East Asian countries such as Japan and Korea, traditional medicine is a fundamental part of the national medical and health system and holds an equal position with modern medicine... In Europe, more than 60% of the population has made traditional medicine a part of their medical regimen. Europe now represents 44.5% of the global herbal market... In 2015, China boasted USD3.77 billion in revenues from the export of Chinese medicine with Southeast and South Asia serving as both the traditional and the principal destinations." The business already represented by the current figures is proof of the huge potential for further development of traditional medicine.

New policies that are conducive to the globalization of Chinese medicine continue to make their appearance. In 2015, the Chinese government rolled out a landmark initiative with the long title of "Vision and Actions on Jointly Building a Silk Road Economic Belt and a 21st Century Maritime Silk Road", but quickly becoming known the world over in its abbreviated form, the One Belt and One Road initiative, the goal of which is to promote international connections and communication as well as bilateral trade.

At the conference, Pansy Yau, deputy director of research at the Hong Kong Trade Development Council explained: "The scale and ambition of the Belt and Road Initiative means it will accelerate development of Eurasian countries along the proposed economic corridors. It may also have significant implications for the Chinese Medicine sector." Wang Xiaopin, the TCM State Administration general director, also mentioned in her speech: "Looking at it from a global viewpoint, the countries and regions that are most open to treating Chinese medicine as real forms of therapy lie mostly along the routes envisioned by the One Belt and One Road initiative. Almost all 13 domestic and foreign free trade zone (FTA) agreements China has signed include Chinese medicine as a component."

The globalization of Chinese medicine nevertheless still faces several difficulties and challenges, despite the great market demand and the support afforded by the government policies. For instance, due to their being no standardization in place between the different local systems as well as a divergence in economic development, culture and religion, a practicable research methodology and an international standard are yet to be established. There are also legal obstacles, trade barriers, among other hurdles. Dr. Burt Kroes from the Medicines Evaluation Board in the Netherlands shared information concerning the quality control of (traditional) herbal medicinal products in the EU market with the guests at the conference, enabling guests to gain more knowledge about how to make Chinese medicine enter the global market.

In addition, the conference invited professors in the field of Chinese medicine from The University of Hong Kong, the University of Macau and Nanjing University of Chinese Medicine, and corporate representatives from Chinese medicine producers such as Hong Kong-based Nong's and Beijing-based Tong Ren Tang, to join experts in other fields in a move to share the latest research achievements and development in terms of laws and regulations affecting Chinese medicine as well as cases of successful products.

This year, a new member of LKK Health Products Group, China-based Naturale (China) Pharma Co., Ltd., again took part in the conference. Naturale was established in 2015, specializing in the cultivation and sales of Chinese medicinal herbs. Naturale has built production facilities for codonopsis pilosula, astragalus mongholicus, poria, ganoderma lucidum, goji berry, lentinus edodes, chrysanthemum morifolium and morinda officinalis, choosing the best locations across China for the various facilities.

In 2016, Naturale signed an agreement with Japan-based Takasago Pharmaceutical Co. Ltd., a subsidiary of Ohsugi Pharmaceutical Co. Ltd., one of the four biggest Chinese medicine producers in Japan, with the first order including saffron crocus, semen coicis, astragalus mongholicus, poria, among other herbs. With such practice, authentic Chinese medicine has successfully entered the international market.

About LKK Health Products Group (WWW.LKKHPG.COM)

LKK Health Products Group ("LKKHPG") is a member of Lee Kum Kee Group, a century-old Hong Kong enterprise. Headquartered in Hong Kong, LKKHPG is a modern diversified business group that specializes in R&D, production, sales and services of Chinese herbal health products; TCM plantation management and sales of raw Chinese medicinal materials; mobile internet platform and related products and services; and property investment.

As of 30 June 2016, LKKHPG employs approximately 4,800 staff. Members of LKKHPG include Infinitus (China) Company Ltd., Infinitus (Hong Kong) Company Ltd., Infinitus International Company Ltd., Infinitus International (Malaysia) Sdn Bhd., Infinitus Health Products (Singapore) Pte Ltd., Infinitus Innovations (Canada) Inc., Naturale (China) Pharma Co., Ltd., HeHa Digital Health Ltd. and Infinitus Property Investment (Hong Kong) Limited.

Photo - http://photos.prnasia.com/prnh/20160831/0861608903

Source: LKK Health Products Group
Related Links:
collection